Leukocyte chemotactic activity of cyclophilin.

Xu, Qin; Leiva, María C.; Fischkoff, Steven A.; Handschumacher, Robert E.; Lyttle, C. Richard

doi:10.1016/s0021-9258(19)49791-3

Cited by 181 publications

(29 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, extracellular CypA is a potent chemoattractant for inflammatory cells. 23,28 CypA has been implicated in the following pathologies: viral infections, 29 neurodegeneration, 30 cancer, 31 rheumatoid arthritis, 32 sepsis, 33 asthma, 34 periodontitis, 35 and ageing. 36 Recently, we have demonstrated the involvement of both intracellular and extracellular CypA in several CVDs.…”

Section: Cyclophilin Amentioning

confidence: 99%

“…54,55 Conversely, extracellular CypB, like CypA, was found to induce the chemotaxis of inflammatory cells into damaged tissues. 23,28,56,57 In particular, CypB induced integrin-mediated cell adhesion by its interaction with CD147, CD98, integrins, 58 which was dependent on protein kinase (PK) C-delta activation and was critical for ERK1/2-mediated signalling. CypB has been associated with osteogenesis imperfecta, 49,59 cancer, 55,60,61 CMV infection, 62,63 HIV, 64 neurodegeneration, 65 asthma, 34 and ageing.…”

Section: Cyclophilin Bmentioning

confidence: 99%

See 1 more Smart Citation

Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases

Perrucci

Gowran

Zanobini

et al. 2015

Cardiovascular Research

View full text Add to dashboard Cite

Peptidyl-prolyl cis-trans-isomerases are a highly conserved family of immunophilins. The three peptidyl-prolyl cis-trans-isomerase subfamilies are cyclophilins, FK-506-binding proteins, and parvulins. Peptidyl-prolyl cis-trans-isomerases are expressed in multiple human tissues and regulate different cellular functions, e.g. calcium handling, protein folding, and gene expression. Moreover, these subfamilies have been shown to be consistently involved in several cardiac and vascular diseases including heart failure, arrhythmias, vascular stenosis, endothelial dysfunction, atherosclerosis, and hypertension. This review provides a concise description of the peptidyl-prolyl cis-trans-isomerases and presents an incisive selection of studies focused on their relationship with cardiovascular diseases.

show abstract

Section: Cyclophilin Amentioning

confidence: 99%

Section: Cyclophilin Bmentioning

confidence: 99%

Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases

Perrucci

Gowran

Zanobini

et al. 2015

Cardiovascular Research

View full text Add to dashboard Cite

show abstract

“…Previous reports have shown that CypA is secreted by various cell types upon stimulation, such as LPS‐induced macrophages and LPS‐stimulated smooth muscle cells, and then released upon cell death 14,19‐22 . Secreted CypA can induce signaling transduction via extracellular binding and peptidyl‐prolyl cis‐trans isomerase activity in proline residues of CD147 17,23,24 .…”

Section: Discussionmentioning

confidence: 99%

Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells‐2 (TREM2)

Kim

Yee

et al. 2021

The FASEB Journal

View full text Add to dashboard Cite

show abstract

“…The secretion of CyPA is mediated via a vesicular transport pathway that depends on the Rho-kinase activation ( 64 ). The secreted form of CyPA acts as a chemoattractant for monocytes and leukocytes ( 63 , 65 , 66 ). To date, although several functions of most cyclophilin isoforms remain unknown, the different isoforms of cyclophilins exhibit domain-specific properties apart from their function as chaperones.…”

Section: Function Of Cyclophilinsmentioning

confidence: 99%

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?

et al. 2021

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is now at the forefront of major health challenge faced globally, creating an urgent need for safe and efficient therapeutic strategies. Given the high attrition rates, high costs, and quite slow development of drug discovery, repurposing of known FDA-approved molecules is increasingly becoming an attractive issue in order to quickly find molecules capable of preventing and/or curing COVID-19 patients. Cyclosporin A (CsA), a common anti-rejection drug widely used in transplantation, has recently been shown to exhibit substantial anti-SARS-CoV-2 antiviral activity and anti-COVID-19 effect. Here, we review the molecular mechanisms of action of CsA in order to highlight why this molecule seems to be an interesting candidate for the therapeutic management of COVID-19 patients. We conclude that CsA could have at least three major targets in COVID-19 patients: (i) an anti-inflammatory effect reducing the production of proinflammatory cytokines, (ii) an antiviral effect preventing the formation of the viral RNA synthesis complex, and (iii) an effect on tissue damage and thrombosis by acting against the deleterious action of angiotensin II. Several preliminary CsA clinical trials performed on COVID-19 patients report lower incidence of death and suggest that this strategy should be investigated further in order to assess in which context the benefit/risk ratio of repurposing CsA as first-line therapy in COVID-19 is the most favorable.

show abstract

Leukocyte chemotactic activity of cyclophilin.

Cited by 181 publications

References 49 publications

Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases

Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases

Cyclophilin A is an endogenous ligand for the triggering receptor expressed on myeloid cells‐2 (TREM2)

Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?

Contact Info

Product

Resources

About